HIV-1 Integrase Genotype

Last Modified: 3/27/2019 3:45:55 PM

Medical Necessity Documentation:  
Client Notes:  
Patient Preparation:  
Specimen Requirements:

2.0 mL FROZEN Plasma from a Lavender Top Tube - EDTA in a Plastic Vial

Collection Instructions: Value of last viral load and date of last viral load must be provided with the order

Separate plasma from the cells by centrifugation within 24 hours after collection.

Minimum Volume: 0.6 mL Plasma
Transport & Storage: Temperature/Stability: 24 hours Ambient
5 days Refrigerated
35 days Frozen (Preferred)

Ship frozen.
Rejection Criteria: Gross hemolysis • Lipemia • Serum • Non-centrifuged PPT • Frozen PPT (in situ) • Heparinized plasma
Reference Range: Refer to Interpretive Results
Critical Ranges:  
Test Comments:  
Methodology: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) • Sequencing
Clinical Significance: The emergence of integrase drug resistance mutations has been observed in vitro and in patients experiencing virologic failure on raltegravir in clinical trials. Twenty three percent of patients receiving raltegravir in a clinical trial experienced virologic failure at 48 weeks and genotypic analysis detected raltegravir associated resistance mutations in 68% of virologic failures. This assay amplifies and sequences the HIV-1 integrase gene and reports mutations at positions associated with integrase inhibitor drug resistance.
Custom Panel: No


Turn Around Time: 5 to 8 days
Days Performed: Monday, Friday
PHL Test Code: HIVI
EPIC Test Code: IMO1957
Send Out Test Code: 16868
Alternate Test Names: Elvitegravir; HIV Integrase Genotype; HIV-1 Integrase Mutations; HIV-1 Integrase Strand Transfer Inhibitor; Isentress (Raltegravir, MK-0518) Resistance; MK-0518; Raltegravir
Included Tests:  
CPT Coding: 87906

Go back to the top of the page.